Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Royalty Pharma
RPRX
|
+$709M |
| 2 |
WIX.com
WIX
|
+$282M |
| 3 |
Spotify
SPOT
|
+$279M |
| 4 |
Mercado Libre
MELI
|
+$249M |
| 5 |
Roblox
RBLX
|
+$228M |
Top Sells
| 1 |
KE Holdings
BEKE
|
+$298M |
| 2 |
CBRE Group
CBRE
|
+$283M |
| 3 |
Tesla
TSLA
|
+$275M |
| 4 |
Amazon
AMZN
|
+$256M |
| 5 |
NVIDIA
NVDA
|
+$237M |
Sector Composition
| 1 | Consumer Discretionary | 27.47% |
| 2 | Healthcare | 25.5% |
| 3 | Technology | 17.5% |
| 4 | Communication Services | 10.66% |
| 5 | Financials | 6.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HUYA
226
Huya Inc
HUYA
$760M
| $6.85M | 0.01% |
1,765,711
-368,029
| -17% | -$1.43M |
|
227
Butterfly Network
BFLY
$385M
| $6.27M | 0.01% |
2,040,969
-174,661
| -8% | -$536K |
|
228
Health Catalyst
HCAT
$233M
| $5.69M | 0.01% |
392,517
-47,650
| -11% | -$691K |
|
229
Clover Health Investments
CLOV
$1.48B
| $5.66M | 0.01% |
2,645,503
-5,142,177
| -66% | -$11M |
|
|
NBTX
230
Nanobiotix
NBTX
$453M
| $5.39M | 0.01% |
1,400,000
| – | – |
|
231
Allbirds
BIRD
$50M
| $5.38M | 0.01% |
68,404
| – | – |
|
232
FTI Consulting
FCN
$5.27B
| $5.32M | 0.01% |
+29,413
| New | +$5.32M |
|
233
Fortive
FTV
$16.2B
| $5.32M | 0.01% |
97,814
| – | – |
|
|
API
234
Agora
API
$339M
| $4.89M | 0.01% |
744,300
| – | – |
|
235
AutoZone
AZO
$71.2B
| $4.74M | ﹤0.01% |
+2,205
| New | +$4.74M |
|
|
DCBO
236
Docebo
DCBO
$868M
| $4.62M | ﹤0.01% |
161,308
+21,544
| +15% | +$617K |
|
237
Lyell Immunopharma
LYEL
$257M
| $4.62M | ﹤0.01% |
35,383
-3,854
| -10% | -$503K |
|
238
HUTCHMED
HCM
$2.71B
| $4.61M | ﹤0.01% |
364,979
-813
| -0.2% | -$10.3K |
|
239
Cognizant
CTSH
$33.8B
| $4.53M | ﹤0.01% |
+67,105
| New | +$4.53M |
|
240
GitLab
GTLB
$7.95B
| $4.48M | ﹤0.01% |
+84,315
| New | +$4.48M |
|
241
BridgeBio Pharma
BBIO
$10.1B
| $4.4M | ﹤0.01% |
484,477
-57,414
| -11% | -$521K |
|
242
Electronic Arts
EA
$42.2B
| $4.31M | ﹤0.01% |
35,446
+35,282
| +21,513% | +$4.29M |
|
|
RUBY
243
DELISTED
Rubius Therapeutics, Inc
RUBY
| $4.17M | ﹤0.01% |
4,906,078
-1,393
| -0% | -$1.19K |
|
244
CarMax
KMX
$9.07B
| $4.04M | ﹤0.01% |
+44,597
| New | +$4.04M |
|
245
M&T Bank
MTB
$31.1B
| $3.94M | ﹤0.01% |
+24,709
| New | +$3.94M |
|
246
Progressive
PGR
$144B
| $3.92M | ﹤0.01% |
+33,746
| New | +$3.92M |
|
247
CureVac
CVAC
$1.21B
| $3.91M | ﹤0.01% |
287,249
-3,624,098
| -93% | -$49.3M |
|
248
Texas Instruments
TXN
$167B
| $3.7M | ﹤0.01% |
+24,059
| New | +$3.7M |
|
249
Relay Therapeutics
RLAY
$686M
| $3.68M | ﹤0.01% |
219,622
-24,655
| -10% | -$413K |
|
|
MTLS
250
Materialise
MTLS
$303M
| $3.65M | ﹤0.01% |
268,000
| – | – |
|